Compare LRN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | DYN |
|---|---|---|
| Founded | 2000 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2007 | 2020 |
| Metric | LRN | DYN |
|---|---|---|
| Price | $75.19 | $15.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $102.50 | $34.33 |
| AVG Volume (30 Days) | 850.7K | ★ 2.2M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $917,734,000.00 | N/A |
| Revenue This Year | $2.10 | N/A |
| Revenue Next Year | $4.63 | N/A |
| P/E Ratio | $52.55 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $14.00 |
| 52 Week High | $103.67 | $27.31 |
| Indicator | LRN | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 38.49 |
| Support Level | $73.87 | $14.43 |
| Resistance Level | $84.08 | $19.48 |
| Average True Range (ATR) | 2.54 | 0.96 |
| MACD | 0.03 | -0.21 |
| Stochastic Oscillator | 22.51 | 0.56 |
Stride Inc is a technology company providing an educational platform to deliver proprietary and third-party curriculum, software systems, and educational services designed to facilitate individualized learning for students and adults throughout the U.S. The platform delivers products and services to attract, enroll, educate, track progress, and support students. It provides customized solutions to public and private schools, school districts, charter boards, employers, government agencies, and consumers. Its platform addresses two markets in the K-12 space: General Education and Career Learning, with products and services for the General Education market predominantly focused on core subjects for kindergarten through twelfth grade students.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.